Cantor Fitzgerald Reiterates “Overweight” Rating for COMPASS Pathways (NASDAQ:CMPS)

Cantor Fitzgerald restated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a report issued on Friday,Benzinga reports.

Several other equities research analysts have also commented on CMPS. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group dropped their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways has a consensus rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Trading Down 4.9 %

Shares of CMPS stock opened at $2.94 on Friday. The stock has a 50 day simple moving average of $3.86 and a 200-day simple moving average of $4.73. COMPASS Pathways has a 1-year low of $2.88 and a 1-year high of $10.31. The company has a market cap of $272.46 million, a price-to-earnings ratio of -1.34 and a beta of 2.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). On average, equities research analysts expect that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP purchased a new position in COMPASS Pathways during the fourth quarter worth about $11,714,000. Altium Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $5,384,000. Tang Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter valued at approximately $3,780,000. Nantahala Capital Management LLC lifted its holdings in COMPASS Pathways by 400.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock valued at $3,780,000 after acquiring an additional 800,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in COMPASS Pathways in the fourth quarter worth approximately $2,458,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.